lerodalcibep

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Heterozygous Familial Hypercholesterolemia

Conditions

Heterozygous Familial Hypercholesterolemia

Trial Timeline

Apr 22, 2021 → Dec 5, 2023

NCT ID

NCT04797104

About lerodalcibep

lerodalcibep is a phase 3 stage product being developed by Medpace for Heterozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04797104. Target conditions include Heterozygous Familial Hypercholesterolemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05234775	Phase 3	Completed	Jan 28, 2022	Jul 11, 2022	Hypercholesterolemia
NCT04797104	Phase 3	Completed	Apr 22, 2021	Dec 5, 2023	Heterozygous Familial Hypercholesterolemia
NCT04797247	Phase 3	UNKNOWN	Apr 22, 2021	Feb 28, 2024	Cardiovascular Diseases
NCT04806893	Phase 3	UNKNOWN	Apr 22, 2021	Feb 28, 2024	Cardiovascular Risk Factor
NCT04798430	Phase 3	Recruiting	Dec 3, 2020	Dec 31, 2025	Cardiovascular Disease With Mention of Arteriosclerosis

Competing Products

18 competing products in Heterozygous Familial Hypercholesterolemia

See all competitors

Product	Company	Stage	Hype Score
AZD0780 + Placebo	AstraZeneca	Phase 3	77
Anacetrapib + Placebo for anacetrapib	Merck	Phase 3	77
Enlicitide Decanoate + Placebo	Merck	Phase 2/3	65
Inclisiran	Novartis	Phase 3	77
Inclisiran + Placebo	Novartis	Phase 3	77
Fluvastatin	Novartis	Phase 3	77
Inclisiran + Placebo	Novartis	Phase 3	77
Evolocumab + Placebo	Amgen	Phase 3	76
Bococizumab (PF-04950615;RN316)	Pfizer	Phase 3	76
Atorvastatin + Atorvastatin	Pfizer	Phase 1	32
IBI306 + placebo	Innovent Biologics	Phase 3	76
Lumacaftor Plus Ivacaftor Combination + Ivacaftor	Vertex Pharmaceuticals	Phase 3	76
LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo	Sanofi	Phase 3	76
Placebo + Alirocumab	Sanofi	Phase 3	76
Praluent	Sanofi	Approved	84
AK102 + Placebo + Statins and/or Ezetimibe	Akeso	Phase 2	51
mipomersen sodium + placebo	Ionis Pharmaceuticals	Phase 3	74
MGL-3196 (resmetirom) + Placebo	Madrigal Pharmaceuticals	Phase 2	49

Other Products from Medpace

Lesinurad + XOI + Placebo + colchicine + corticosteroidsApproved

VI-0521 + VI-0521 + Placebo matched phentermine/topiramatePhase 3

TNX-103 + PlaceboPhase 3

lerodalcibepPhase 3

Flutemetamol (18F) InjectionPhase 3